Malaysian Genomics Resource
Malaysian Genomics Resource Centre Berhad, together with its subsidiaries, provides genetics, genomics, immunotherapy, and biopharmaceutical services worldwide. Its flagship product, Dtect genetic screening tests which inspects DNA for markers associated with genetic variations that influence various biological processes. The company also offers genome sequencing services for humans, animals, pla… Read more
Market Cap & Net Worth: Malaysian Genomics Resource (0155)
Malaysian Genomics Resource (KLSE:0155) has a market capitalization of $5.79 Million (RM26.07 Million) as of March 19, 2026. Listed on the KLSE stock exchange, this Malaysia-based company holds position #34413 globally and #895 in its home market, demonstrating a -5.00% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Malaysian Genomics Resource's stock price RM0.19 by its total outstanding shares 137210480 (137.21 Million).
Malaysian Genomics Resource Market Cap History: 2015 to 2026
Malaysian Genomics Resource's market capitalization history from 2015 to 2026. Data shows change from $22.85 Million to $5.79 Million (-9.78% CAGR).
Malaysian Genomics Resource Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Malaysian Genomics Resource's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
1.32x
Malaysian Genomics Resource's market cap is 1.32 times its annual revenue
0.72x
Higher than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $16.76 Million | $10.43 Million | $1.74 Million | 1.61x | 9.64x |
| 2017 | $10.66 Million | $9.87 Million | $589.30K | 1.08x | 18.09x |
| 2018 | $7.16 Million | $26.16 Million | -$4.53 Million | 0.27x | N/A |
| 2019 | $12.34 Million | $283.06K | -$3.84 Million | 43.59x | N/A |
| 2020 | $31.07 Million | $951.35K | $17.10 Million | 32.66x | 1.82x |
| 2021 | $35.34 Million | $1.78 Million | -$4.29 Million | 19.81x | N/A |
| 2022 | $23.31 Million | $28.36 Million | $7.21 Million | 0.82x | 3.23x |
| 2023 | $13.56 Million | $8.36 Million | -$14.25 Million | 1.62x | N/A |
| 2024 | $10.51 Million | $12.86 Million | -$21.51 Million | 0.82x | N/A |
| 2025 | $7.31 Million | $5.52 Million | -$4.19 Million | 1.32x | N/A |
Competitor Companies of 0155 by Market Capitalization
Companies near Malaysian Genomics Resource in the global market cap rankings as of March 19, 2026.
Key companies related to Malaysian Genomics Resource by market ranking:
- Thermo Fisher Scientific Inc (NYSE:TMO): Ranked #93 globally with a market cap of $174.19 Billion USD.
- Danaher Corporation (NYSE:DHR): Ranked #150 globally with a market cap of $120.45 Billion USD.
- IDEXX Laboratories Inc (NASDAQ:IDXX): Ranked #468 globally with a market cap of $45.61 Billion USD.
- Lonza Group Ltd (PINK:LZAGF): Ranked #507 globally with a market cap of $41.73 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #93 | Thermo Fisher Scientific Inc | NYSE:TMO | $174.19 Billion | $464.69 |
| #150 | Danaher Corporation | NYSE:DHR | $120.45 Billion | $191.50 |
| #468 | IDEXX Laboratories Inc | NASDAQ:IDXX | $45.61 Billion | $577.12 |
| #507 | Lonza Group Ltd | PINK:LZAGF | $41.73 Billion | $596.13 |
Malaysian Genomics Resource Historical Marketcap From 2015 to 2026
Between 2015 and today, Malaysian Genomics Resource's market cap moved from $22.85 Million to $ 5.79 Million, with a yearly change of -9.78%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | RM5.79 Million | -20.83% |
| 2025 | RM7.31 Million | -30.43% |
| 2024 | RM10.51 Million | -22.47% |
| 2023 | RM13.56 Million | -41.83% |
| 2022 | RM23.31 Million | -34.05% |
| 2021 | RM35.34 Million | +13.73% |
| 2020 | RM31.07 Million | +151.85% |
| 2019 | RM12.34 Million | +72.34% |
| 2018 | RM7.16 Million | -32.86% |
| 2017 | RM10.66 Million | -36.36% |
| 2016 | RM16.76 Million | -26.67% |
| 2015 | RM22.85 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 19th, 2026 the market cap of Malaysian Genomics Resource was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $5.79 Million USD |
| MoneyControl | $5.79 Million USD |
| MarketWatch | $5.79 Million USD |
| marketcap.company | $5.79 Million USD |
| Reuters | $5.79 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.